CorMedix vs Liquidia
CRMD and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMD and LQDA compare
Liquidia is the larger company, worth 14 times as much as CorMedix ($5.1B against $364M).
Liquidia grew revenue faster over the last twelve months (2234% versus 281% for CorMedix).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with 30.7% at Liquidia.
CorMedix scores higher on the StockData Score (13 against 8 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMD | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $364M | $5.1B |
| Share price | $4.67 | $56.73 |
| Change, 1 year | −58.5% | 102% |
| Change, 5 years | −7.9% | 1280% |
| Beta (5Y) | 0.49 | 1.00 |
| Employees | 191 | 216 |
| StockData Score | ||
| Total score | 13 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 40.8× |
| P/S | 0.8× (better) | 11.3× |
| P/B | 0.8× (better) | 26.0× |
| EV/EBITDA | 0.5× (better) | 28.2× |
| P/FCF | 1.5× (better) | 33.7× |
| FCF yield | 68.8% (better) | 3.0% |
| Fair value | – | $32.46 |
| Margin of safety | – | −74.8% |
| Growth | ||
| Revenue growth (TTM) | 281% | 2234% (better) |
| Revenue growth, 5Y average | 320% (better) | 192% |
| Net income growth (TTM) | 266% | – |
| Profitability | ||
| Gross margin | 82.8% | – |
| Operating margin | 47.0% (better) | 37.4% |
| Net margin | 40.5% (better) | 30.7% |
| FCF margin | 54.2% (better) | 33.4% |
| Return on equity | 54.9% | 132% (better) |
| Return on invested capital | 171% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 6.3× |
| Current ratio | 2.56 (better) | 2.31 |
| Altman Z-score | 2.01 | 10.49 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.28% | – |
| Shareholder yield | −0.28% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 56.5% | 81.1% |
| Held by insiders | 3.3% | 19.5% |
| Insider net buying, 12 months | −$1.6M (better) | −$227M |
| Short interest, % of float | 18.8% | 24.3% |
Go deeper
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.